Friedrich-Miescher-Strasse 15
Tübingen 72076
Germany
49 7071 9883 0
https://www.curevac.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees:
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Sarah Fakih | Vice President Corporate Communications & Investor Relations | N/A | N/A | N/A |
Mr. Marco Rau L.L.M., Ph.D. | General Counsel | N/A | N/A | N/A |
Slavica Stevanovic-Heck | Head of Human Resources | N/A | N/A | N/A |
Dr. Patrick Baumhof | Senior Vice President of Technology | N/A | N/A | N/A |
Mr. Ronald Plasterk | Senior Vice President of Science & Innovation | N/A | N/A | N/A |
Marcus Dalton | Head of Intellectual Property | N/A | N/A | N/A |
Dr. Hans-Georg Rammensee Ph.D. | Scientific Director of Immunology and Member of Scientific Advisory Board | N/A | N/A | N/A |
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company also develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
CureVac N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.